JOP20200031A1 - طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة - Google Patents

طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة

Info

Publication number
JOP20200031A1
JOP20200031A1 JOP/2020/0031A JOP20200031A JOP20200031A1 JO P20200031 A1 JOP20200031 A1 JO P20200031A1 JO P20200031 A JOP20200031 A JO P20200031A JO P20200031 A1 JOP20200031 A1 JO P20200031A1
Authority
JO
Jordan
Prior art keywords
methods
osteoarthritis
treating osteoarthritis
patient
cannabidiol
Prior art date
Application number
JOP/2020/0031A
Other languages
English (en)
Inventor
Donna Gutterman
Griesser James
Nancy Tich
Daniel Clauw
Smith Ted
John Messenheimer
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of JOP20200031A1 publication Critical patent/JOP20200031A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلية، وطرق لاستخدام تركيبة صيدلية، لعلاج الالتهاب العظمي المفصلي في خاضع للعلاج في حاجة لذلك، تتضمن التركيبة الصيدلية كانابيديول أو ملحًا مقبولاً صيدليًا منه؛ وبخاصة حيثما يكون إعطاء الكانابيديول بواسطة تركيبة هلام صيدلية عبر الأدمة. يتم الكشف عن طريقة لعلاج واحد أو أكثر من أعراض الالتهاب العظمي المفصلي في مريض. تتضمن الطريقة إعطاء مقدار فعال من الكانابيديول عبر الأدمة (CBD) إلى المريض حيث يتم علاج واحد أو أكثر من أعراض الالتهاب العظمي المفصلي في المريض.
JOP/2020/0031A 2017-08-14 2018-08-13 طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة JOP20200031A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US201862661733P 2018-04-24 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
JOP20200031A1 true JOP20200031A1 (ar) 2020-02-12

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0031A JOP20200031A1 (ar) 2017-08-14 2018-08-13 طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة

Country Status (11)

Country Link
US (4) US20200170963A1 (ar)
EP (1) EP3668500A4 (ar)
JP (3) JP2020530857A (ar)
KR (1) KR20200054171A (ar)
AU (2) AU2018318425A1 (ar)
BR (1) BR112020003025A2 (ar)
CA (1) CA3072849A1 (ar)
IL (2) IL301622A (ar)
JO (1) JOP20200031A1 (ar)
MX (1) MX2020001768A (ar)
WO (1) WO2019034985A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
EP4041210B1 (en) * 2019-10-13 2026-03-18 FibroBiologics, Inc. Combination of cannabidiol and fibroblasts for use in the treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
EP1890727B1 (en) * 2005-05-25 2012-10-03 CaloSyn Pharma, Inc Method and composition for treating osteoarthritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
CN102271705A (zh) * 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
KR20150056522A (ko) * 2012-06-26 2015-05-26 앰버데일 엔터프라이지즈 피티와이 리미티드 초음파 공동화에 의한 지방 조직으로부터 줄기 세포의 분리 및 이의 이용 방법
EP3177286A4 (en) * 2014-07-18 2018-05-16 Medipath Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Also Published As

Publication number Publication date
EP3668500A1 (en) 2020-06-24
IL272593A (en) 2020-03-31
JP2025024068A (ja) 2025-02-19
US20200170963A1 (en) 2020-06-04
JP2020530857A (ja) 2020-10-29
EP3668500A4 (en) 2021-04-28
IL301622A (en) 2023-05-01
US20250268843A1 (en) 2025-08-28
JP2023109969A (ja) 2023-08-08
CA3072849A1 (en) 2019-02-21
US20240189255A1 (en) 2024-06-13
MX2020001768A (es) 2020-12-03
KR20200054171A (ko) 2020-05-19
AU2018318425A1 (en) 2020-02-27
JP7590803B2 (ja) 2024-11-27
BR112020003025A2 (pt) 2020-08-04
AU2024205778A1 (en) 2024-09-05
WO2019034985A1 (en) 2019-02-21
US20240148669A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
MX2022012001A (es) Tratamiento preventivo de la migra?a.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
EA202190294A1 (ru) Комбинированная терапия для лечения рака
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
EA202190291A1 (ru) Комбинированная терапия для лечения рака
RU2013122842A (ru) Способ лечения синдрома диабетической стопы
EA202092278A1 (ru) Римегепант для связанных с cgrp расстройств